Plant modernization includes seven new manufacturing and packaging lines, enabling production of 14 new products
MONTREAL—Merck Canada has completed the $33.2-million modernization of its Pointe Claire manufacturing plant, establishing the facility as a Centre of Excellence for manufacturing liquids, ointments and creams.
Merck expanded plant capabilities and installed new production equipment. It will also refit production and storage areas to increase competitiveness internationally and preserve local jobs.
The modernization project began with the construction of a new 56,500-square-foot warehouse, which includes seven new manufacturing and packaging lines to produce of 14 new products.
The Pointe Claire plant, which employs 264 people, is one of the facilities in Merck’s global network outside of the U.S. to have received QSP-2 certification from the U.S. Food and Drug Administration, which permits Canadian products to be exported to the U.S.
In total, $20 million of the overall investment went toward the purchase of goods and services from Quebec suppliers.
Based in Montreal, Merck is a global health care manufacturer of prescription medicines, vaccines, consumer and animal health products.
The company invested $78.6 million in R&D activities in 2010 and employs over 1,400 people across Canada.